{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:54:19Z","timestamp":1791917659237,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To explore the possibility of kidney organoids generated using patient derived human induced pluripotent stem cells (hiPSC) for modeling of Fabry disease nephropathy (FDN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      First, we generated hiPSC line using peripheral blood mononuclear cells (PBMCs) from two male FD-patients with different types of\n                      <jats:italic>GLA<\/jats:italic>\n                      mutation: a classic type mutation (CMC-Fb-001) and a non-classic type (CMC-Fb-003) mutation. Second, we generated kidney organoids using wild-type (WT) hiPSC (WTC-11) and mutant hiPSCs (CMC-Fb-001 and CMC-Fb-003). We then compared alpha-galactosidase A (\u03b1-GalA) activity, deposition of globotriaosylceremide (Gb-3), and zebra body formation under electromicroscopy (EM).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both FD patients derived hiPSCs had the same mutations as those detected in PBMCs of patients, showing typical pluripotency markers, normal karyotyping, and successful tri-lineage differentiation. Kidney organoids generated using WT-hiPSC and both FD patients derived hiPSCs expressed typical nephron markers without structural deformity. Activity of \u03b1-GalA was decreased and deposition of Gb-3 was increased in FD patients derived hiPSCs and kidney organoids in comparison with WT, with such changes being far more significant in CMC-Fb-001 than in CMC-Fb-003. In EM finding, multi-lammelated inclusion body was detected in both CMC-Fb-001 and CMC-Fb-003 kidney organoids, but not in WT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Kidney organoids generated using hiPSCs from male FD patients might recapitulate the disease phenotype and represent the severity of FD according to the\n                      <jats:italic>GLA<\/jats:italic>\n                      mutation type.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-023-03992-0","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T12:03:07Z","timestamp":1677067387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system"],"prefix":"10.1186","volume":"21","author":[{"given":"Sheng","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Sil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjin","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Woo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Woo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0048-5717","authenticated-orcid":false,"given":"Byung Ha","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"3992_CR1","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ. Fabry\u2019s disease. Lancet. 2008;372:1427\u201335.","journal-title":"Lancet"},{"key":"3992_CR2","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3892\/ijmm.2012.1139","volume":"30","author":"MH Lee","year":"2012","unstructured":"Lee MH, Choi EN, Jeon YJ, Jung SC. Possible role of transforming growth factor-beta1 and vascular endothelial growth factor in Fabry disease nephropathy. Int J Mol Med. 2012;30:1275\u201380.","journal-title":"Int J Mol Med"},{"key":"3992_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.23876\/j.krcp.20.264","volume":"40","author":"S Chung","year":"2021","unstructured":"Chung S, Son M, Chae Y, Oh S, Koh ES, Kim YK, Shin SJ, Park CW, Jung SC, Kim HS. Fabry disease exacerbates renal interstitial fibrosis after unilateral ureteral obstruction via impaired autophagy and enhanced apoptosis. Kidney Res Clin Pract. 2021;40:208\u201319.","journal-title":"Kidney Res Clin Pract"},{"key":"3992_CR4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.23876\/j.krcp.21.056","volume":"40","author":"IY Kim","year":"2021","unstructured":"Kim IY, Lee HJ, Cheon CK. Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease. Kidney Res Clin Pract. 2021;40:611\u20139.","journal-title":"Kidney Res Clin Pract"},{"key":"3992_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.yjmcc.2018.07.246","volume":"121","author":"Y Kuramoto","year":"2018","unstructured":"Kuramoto Y, Naito AT, Tojo H, Sakai T, Ito M, Shibamoto M, Nakagawa A, Higo T, Okada K, Yamaguchi T, et al. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient. J Mol Cell Cardiol. 2018;121:256\u201365.","journal-title":"J Mol Cell Cardiol"},{"key":"3992_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.kint.2018.08.033","volume":"95","author":"JJ Kang","year":"2019","unstructured":"Kang JJ, Kaissarian NM, Desch KC, Kelly RJ, Shu L, Bodary PF, Shayman JA. alpha-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease. Kidney Int. 2019;95:149\u201359.","journal-title":"Kidney Int"},{"key":"3992_CR7","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.33594\/000000077","volume":"52","author":"F Braun","year":"2019","unstructured":"Braun F, Blomberg L, Brodesser S, Liebau MC, Schermer B, Benzing T, Kurschat CE. Enzyme replacement therapy clears Gb3 deposits from a podocyte cell culture model of Fabry disease but fails to restore altered cellular signaling. Cell Physiol Biochem. 2019;52:1139\u201350.","journal-title":"Cell Physiol Biochem"},{"key":"3992_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100851","volume":"31","author":"HOA Elsaid","year":"2022","unstructured":"Elsaid HOA, Furriol J, Blomqvist M, Diswall M, Leh S, Gharbi N, Anonsen JH, Babickova J, Tondel C, Svarstad E, et al. Reduced alpha-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype. Mol Genet Metab Rep. 2022;31: 100851.","journal-title":"Mol Genet Metab Rep"},{"key":"3992_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.celrep.2014.09.055","volume":"9","author":"FM Drawnel","year":"2014","unstructured":"Drawnel FM, Boccardo S, Prummer M, Delobel F, Graff A, Weber M, Gerard R, Badi L, Kam-Thong T, Bu L, et al. Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. Cell Rep. 2014;9:810\u201321.","journal-title":"Cell Rep"},{"key":"3992_CR10","first-page":"153","volume":"10","author":"BS Freedman","year":"2015","unstructured":"Freedman BS. Modeling kidney disease with iPS cells. Biomark Insights. 2015;10:153\u201369.","journal-title":"Biomark Insights"},{"key":"3992_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/nrd3577","volume":"10","author":"M Grskovic","year":"2011","unstructured":"Grskovic M, Javaherian A, Strulovici B, Daley GQ. Induced pluripotent stem cells\u2013opportunities for disease modelling and drug discovery. Nat Rev Drug Discov. 2011;10:915\u201329.","journal-title":"Nat Rev Drug Discov"},{"key":"3992_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-4939-7471-9_2","volume":"1706","author":"S Kumar","year":"2018","unstructured":"Kumar S, Blangero J, Curran JE. Induced pluripotent stem cells in disease modeling and gene identification. Methods Mol Biol. 2018;1706:17\u201338.","journal-title":"Methods Mol Biol"},{"key":"3992_CR13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijbs.6.796","volume":"6","author":"YS Chun","year":"2010","unstructured":"Chun YS, Chaudhari P, Jang YY. Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int J Biol Sci. 2010;6:796\u2013805.","journal-title":"Int J Biol Sci"},{"key":"3992_CR14","doi-asserted-by":"publisher","first-page":"8715","DOI":"10.1038\/ncomms9715","volume":"6","author":"BS Freedman","year":"2015","unstructured":"Freedman BS, Brooks CR, Lam AQ, Fu H, Morizane R, Agrawal V, Saad AF, Li MK, Hughes MR, Werff RV, et al. Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. Nat Commun. 2015;6:8715.","journal-title":"Nat Commun"},{"key":"3992_CR15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1053\/j.ajkd.2018.02.347","volume":"71","author":"NM Cruz","year":"2018","unstructured":"Cruz NM, Freedman BS. CRISPR gene editing in the kidney. Am J Kidney Dis. 2018;71:874\u201383.","journal-title":"Am J Kidney Dis"},{"key":"3992_CR16","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/nmat4994","volume":"16","author":"NM Cruz","year":"2017","unstructured":"Cruz NM, Song X, Czerniecki SM, Gulieva RE, Churchill AJ, Kim YK, Winston K, Tran LM, Diaz MA, Fu H, et al. Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease. Nat Mater. 2017;16:1112\u20139.","journal-title":"Nat Mater"},{"key":"3992_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.34067\/KID.0000422019","volume":"1","author":"E Liu","year":"2020","unstructured":"Liu E, Radmanesh B, Chung BH, Donnan MD, Yi D, Dadi A, Smith KD, Himmelfarb J, Li M, Freedman BS, Lin J. Profiling APOL1 nephropathy risk variants in genome-edited kidney organoids with single-cell transcriptomics. Kidney. 2020;1:203\u201315.","journal-title":"Kidney"},{"key":"3992_CR18","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s12276-021-00683-y","volume":"53","author":"JW Kim","year":"2021","unstructured":"Kim JW, Kim HW, Nam SA, Lee JY, Cho HJ, Kim TM, Kim YK. Human kidney organoids reveal the role of glutathione in Fabry disease. Exp Mol Med. 2021;53:1580\u201391.","journal-title":"Exp Mol Med"},{"key":"3992_CR19","first-page":"e54650","volume":"118","author":"YA Rim","year":"2016","unstructured":"Rim YA, Nam Y, Ju JH. Induced pluripotent stem cell generation from blood cells using Sendai virus and centrifugation. J Vis Exp. 2016;118:e54650\u20136.","journal-title":"J Vis Exp"},{"key":"3992_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2021.102214","volume":"51","author":"S Cui","year":"2021","unstructured":"Cui S, Shin YJ, Ko EJ, Lim SW, Ju JH, Lee KI, Lee JY, Yang CW, Chung BH. Human-induced pluripotent stem cell lines (CMCi006-A and CMCi007-A) from a female and male patient with Fabry disease carrying the same frameshift deletion mutation. Stem Cell Res. 2021;51: 102214.","journal-title":"Stem Cell Res"},{"key":"3992_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2020.102110","volume":"49","author":"SW Lim","year":"2020","unstructured":"Lim SW, Shin YJ, Cui S, Ko EJ, Lee KI, Lee JY, Chung BH, Yang CW. Generation of a human induced pluripotent stem cell line (CMCi002-A) from a patient with Gitelman\u2019s syndrome. Stem Cell Res. 2020;49: 102110.","journal-title":"Stem Cell Res"},{"key":"3992_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.23876\/j.krcp.20.252","volume":"40","author":"KW Kim","year":"2021","unstructured":"Kim KW, Shin YJ, Kim BM, Cui S, Ko EJ, Lim SW, Yang CW, Chung BH. Modeling of endothelial cell dysfunction using human induced pluripotent stem cells derived from patients with end-stage renal disease. Kidney Res Clin Pract. 2021;40:698\u2013711.","journal-title":"Kidney Res Clin Pract"},{"key":"3992_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100562","volume":"22","author":"T Sawada","year":"2020","unstructured":"Sawada T, Kido J, Yoshida S, Sugawara K, Momosaki K, Inoue T, Tajima G, Sawada H, Mastumoto S, Endo F, et al. Newborn screening for Fabry disease in the western region of Japan. Mol Genet Metab Rep. 2020;22: 100562.","journal-title":"Mol Genet Metab Rep"},{"key":"3992_CR24","first-page":"9385361","volume":"2019","author":"SN Lee","year":"2019","unstructured":"Lee SN, Kim GH, Yoo KD. A Case of a 50-year-old woman with typical Fabry disease who showed serial electrocardiographic and echocardiographic changes over a 17-year period. Case Rep Cardiol. 2019;2019:9385361.","journal-title":"Case Rep Cardiol"},{"key":"3992_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12881-016-0338-7","volume":"17","author":"Y Chong","year":"2016","unstructured":"Chong Y, Kim M, Koh ES, Shin SJ, Kim HS, Chung S. Identification of a novel GLA mutation (Y88C) in a Korean family with Fabry nephropathy: a case report. BMC Med Genet. 2016;17:76.","journal-title":"BMC Med Genet"},{"key":"3992_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.stemcr.2018.08.003","volume":"11","author":"S Tanigawa","year":"2018","unstructured":"Tanigawa S, Islam M, Sharmin S, Naganuma H, Yoshimura Y, Haque F, Era T, Nakazato H, Nakanishi K, Sakuma T, et al. Organoids from nephrotic disease-derived iPSCs identify impaired NEPHRIN localization and slit diaphragm formation in kidney podocytes. Stem Cell Rep. 2018;11:727\u201340.","journal-title":"Stem Cell Rep"},{"key":"3992_CR27","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1073\/pnas.0537900100","volume":"100","author":"J Park","year":"2003","unstructured":"Park J, Murray GJ, Limaye A, Quirk JM, Gelderman MP, Brady RO, Qasba P. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc Natl Acad Sci. 2003;100:3450\u20134.","journal-title":"Proc Natl Acad Sci"},{"key":"3992_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1042\/BJ20130825","volume":"456","author":"A Taguchi","year":"2013","unstructured":"Taguchi A, Maruyama H, Nameta M, Yamamoto T, Matsuda J, Kulkarni AB, Yoshioka H, Ishii S. A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis. Biochem J. 2013;456:373\u201383.","journal-title":"Biochem J"},{"key":"3992_CR29","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1681\/ASN.2019050497","volume":"31","author":"B Najafian","year":"2020","unstructured":"Najafian B, Tondel C, Svarstad E, Gubler MC, Oliveira JP, Mauer M. Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss. J Am Soc Nephrol. 2020;31:865\u201375.","journal-title":"J Am Soc Nephrol"},{"key":"3992_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","volume":"53","author":"A Ortiz","year":"2016","unstructured":"Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, Hopkin RJ, Jovanovic A, Linhart A, Maruti SS, et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry. J Med Genet. 2016;53:495\u2013502.","journal-title":"J Med Genet"},{"key":"3992_CR31","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3109\/0886022X.2012.669300","volume":"34","author":"T Nishino","year":"2012","unstructured":"Nishino T, Obata Y, Furusu A, Hirose M, Shinzato K, Hattori K, Nakamura K, Matsumoto T, Endo F, Kohno S. Identification of a novel mutation and prevalence study for fabry disease in Japanese dialysis patients. Ren Fail. 2012;34:566\u201370.","journal-title":"Ren Fail"},{"key":"3992_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.gene.2015.09.088","volume":"575","author":"H Peng","year":"2016","unstructured":"Peng H, Xu X, Zhang L, Zhang X, Peng H, Zheng Y, Luo S, Guo H, Xia K, Li J, et al. GLA variation pE66Q identified as the genetic etiology of Fabry disease using exome sequencing. Gene. 2016;575:363\u20137.","journal-title":"Gene"},{"key":"3992_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.gene.2015.12.024","volume":"578","author":"C Zizzo","year":"2016","unstructured":"Zizzo C, Monte I, Pisani A, Fatuzzo P, Riccio E, Rodolico MS, Colomba P, Uva M, Cammarata G, Alessandro R, et al. Molecular and clinical studies in five index cases with novel mutations in the GLA gene. Gene. 2016;578:100\u20134.","journal-title":"Gene"},{"key":"3992_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.gene.2015.08.018","volume":"574","author":"A Uribe","year":"2015","unstructured":"Uribe A, Mateus HE, Prieto JC, Palacios MF, Ospina SY, Pasqualim G, da Silveira MU, Giugliani R. Identification of mutations in Colombian patients affected with Fabry disease. Gene. 2015;574:325\u20139.","journal-title":"Gene"},{"key":"3992_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13023-018-0792-8","volume":"13","author":"I Vieitez","year":"2018","unstructured":"Vieitez I, Souto-Rodriguez O, Fernandez-Mosquera L, San Millan B, Teijeira S, Fernandez-Martin J, Martinez-Sanchez F, Aldamiz-Echevarria LJ, Lopez-Rodriguez M, Navarro C, Ortolano S. Fabry disease in the Spanish population: observational study with detection of 77 patients. Orphanet J Rare Dis. 2018;13:52.","journal-title":"Orphanet J Rare Dis"},{"key":"3992_CR36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ymgmr.2014.07.005","volume":"1","author":"T Tsukimura","year":"2014","unstructured":"Tsukimura T, Nakano S, Togawa T, Tanaka T, Saito S, Ohno K, Shibasaki F, Sakuraba H. Plasma mutant alpha-galactosidase A protein and globotriaosylsphingosine level in Fabry disease. Mol Genet Metab Rep. 2014;1:288\u201398.","journal-title":"Mol Genet Metab Rep"},{"key":"3992_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/gm13","volume":"1","author":"PD Stenson","year":"2009","unstructured":"Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, Cooper DN. The human gene mutation database: 2008 update. Genome Med. 2009;1:13.","journal-title":"Genome Med"},{"key":"3992_CR38","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/MNH.0000000000000818","volume":"31","author":"KP Schlingmann","year":"2022","unstructured":"Schlingmann KP, de Baaij JHF. The genetic spectrum of Gitelman(-like) syndromes. Curr Opin Nephrol Hypertens. 2022;31:508\u201315.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"3992_CR39","doi-asserted-by":"publisher","first-page":"11414","DOI":"10.3390\/ijms222111414","volume":"22","author":"L Nunez-Gonzalez","year":"2021","unstructured":"Nunez-Gonzalez L, Carrera N, Garcia-Gonzalez MA. Molecular basis, diagnostic challenges and therapeutic approaches of Bartter and Gitelman syndromes: a primer for clinicians. Int J Mol Sci. 2021;22:11414.","journal-title":"Int J Mol Sci"},{"key":"3992_CR40","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3390\/jpm12050766","volume":"12","author":"AK Linn","year":"2022","unstructured":"Linn AK, Maneepitasut W, Tubsuwan A, Kitiyanant N, Phakdeekitcharoen B, Borwornpinyo S, Hongeng S, Phanthong P. Establishment and characterization of MUi027-A: a novel patient-derived cell line of polycystic kidney disease with PKD1 mutation. J Pers Med. 2022;12:766.","journal-title":"J Pers Med"},{"key":"3992_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.stem.2011.06.007","volume":"9","author":"O Bar-Nur","year":"2011","unstructured":"Bar-Nur O, Russ HA, Efrat S, Benvenisty N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell. 2011;9:17\u201323.","journal-title":"Cell Stem Cell"},{"key":"3992_CR42","doi-asserted-by":"publisher","first-page":"20340","DOI":"10.1038\/s41598-022-24581-z","volume":"12","author":"G Khelifi","year":"2022","unstructured":"Khelifi G, Chow T, Whiteley J, Fort V, Humphreys BD, Hussein SMI, Rogers IM. Determining epigenetic memory in kidney proximal tubule cell derived induced pluripotent stem cells using a quadruple transgenic reprogrammable mouse. Sci Rep. 2022;12:20340.","journal-title":"Sci Rep"},{"key":"3992_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13148-021-01019-3","volume":"13","author":"T Di Risi","year":"2021","unstructured":"Di Risi T, Vinciguerra R, Cuomo M, Della Monica R, Riccio E, Cocozza S, Imbriaco M, Duro G, Pisani A, Chiariotti L. DNA methylation impact on Fabry disease. Clin Epigenetics. 2021;13:24.","journal-title":"Clin Epigenetics"},{"key":"3992_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/bs.mcb.2019.05.003","volume":"153","author":"NM Cruz","year":"2019","unstructured":"Cruz NM, Freedman BS. Differentiation of human kidney organoids from pluripotent stem cells. Methods Cell Biol. 2019;153:133\u201350.","journal-title":"Methods Cell Biol"},{"key":"3992_CR45","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, Cv R, Mirzaian M, Wijburg FA, Linthorst GE, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008;105:2812\u20137.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-03992-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-03992-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-03992-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T13:03:55Z","timestamp":1677071035000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-03992-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3992"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-03992-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2259010\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"11 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All subjects provided informed consent for inclusion before they participated in this study. This study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of Seoul St. Mary\u2019s Hospital (KC16TISI0774).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors have declared no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}